A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

This study is testing a new drug called PT0511 in people with advanced or metastatic solid tumors that have a mutation or amplification in a gene called KRAS. KRAS is a gene that, when abnormal, can drive cancer growth, and researchers are looking for new ways to target it. **You may be eligible if...** - You are 18 or older - You have an advanced or metastatic solid tumor confirmed by biopsy - Your tumor has a KRAS mutation or amplification, confirmed by a certified lab test - You have received at least one prior treatment but no more than a certain number of prior therapies - You are in reasonably good overall health **You may NOT be eligible if...** - Your tumor does not have a KRAS mutation or amplification - You have not received any prior treatment, or have received too many prior lines of therapy - You have untreated brain metastases or other serious health conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.